Your cart is currently empty!
oYo-Link
oYo-Link® Antibody Labeling
Simple, fast, site-Specific antibody labeling with only 30 seconds hands-on time
- 2 steps, mix & illuminate
- 30 seconds hands-on time, 2 hours total conjugation time
- Compatible with all common buffers. 90% labeling efficiency of most antibodies
- Label as little as 1 µg of antibody per reaction
Our Products
oYo-Link® DM1
Site-specifically label your antibody with oYo-Link® DM1 drug for cell killing assays to prototype your ADC candidates.
oYo-Link® HRP
Applicable for direct conjugation of HRP to primary antibodies for ELISA, IHC & western blotting.
oYo-Link® Oligo Custom
Label as little as 1 µg of Antibody with your custom Oligo per reaction. Oligos made by IDT. Supports ssDNA and dsDNA up to 80bp or longer in length.
oYo-Link® Epitope Tag
Quick and easy labeling of antibodies with any of 10 epitope tags for simplified and enhanced multiplexing immunoassays.
The oYo-Link® Technology
Simple, fast, site-Specific antibody labeling
How it works
oYo-Link® reagents consist of low molecular weight (~8 kDa), high-affinity antibody-binding domains that possess a photo-crosslinker within their Fc-binding site. Upon illumination with non-damaging Black-light, oYo-Link forms a covalent bond with the antibody.
Site Specific Antibody Labeling
Uniform labeling of up to 2 labels per Antibody on the heavy chain resulting in improved antibody performance, highly uniform product, and consistent, predictable results.
News
View more newsAlphaThera relocates to accommodate the company’s rapid expansion
AlphaThera have announced their relocation to a new larger laboratory and office space within the Pennovation Works Lab Building at the University of Pennsylvania.
AlphaThera announces the launch of oYo-Capture™ Magnetic Beads
For the efficient removal of free oYo-Link® post conjugation AlphaThera has announced the launch of oYo-Capture™ Magnetic Beads, providing researchers with an efficient method of removing free oYo-Link® reagents post antibody conjugation to ensure low background in high sensitivity assays. AlphaThera is well known within the life science research community for their oYo-Link® antibody labeling […]
$1.7M NIH SBIR Phase II Grant Awarded to AlphaThera for Development of ADCs to target Pancreatic Cancer
AlphaThera was awarded an SBIR Phase II grant by the NIH/NCI to further development of ADCs generated by proximity-based sortase-mediated ligation.
Our Blog
Simple. Fast. Site-Specific antibody labeling.